Herpes Zoster Clinical Presentation and Management
Typical Clinical Presentation
- Herpes zoster typically presents with prodromal pain that often precedes the skin findings by 24-72 hours, unilateral vesicular eruption in a dermatomal distribution, progression from erythematous macules to papules and then to vesicles, lesions that continue to erupt for 4-6 days in immunocompetent hosts, and total disease duration of approximately 2 weeks in otherwise healthy individuals 1, 2
- The rash is usually characterized by a unilateral vesicular eruption in a dermatomal distribution 1, 2
- Lesions continue to erupt for 4-6 days in immunocompetent hosts, with a total disease duration of approximately 2 weeks in otherwise healthy individuals 1
Atypical Presentations
- Patients may present with nonspecific lesions that do not initially have the vesicular appearance of typical zoster 2
- The rash might be atypical, localized, faint, or evanescent in some cases, and in individuals with darker skin pigmentation, the rash might be difficult to recognize 3
Risk Factors and Diagnostic Considerations
- Recipients of blood, bone marrow, or solid organ transplants are at higher risk for developing herpes zoster 1, 2
- Tzanck smear showing giant cells can be diagnostic for herpesvirus infection, and vesicle fluid specimens can be obtained for immunofluorescence antigen testing, culture, or PCR to confirm diagnosis 4
- Consider alternative diagnoses that may mimic herpes zoster, especially in the absence of characteristic pain 3
Clinical Implications and Management
- High-dose IV acyclovir is recommended for immunocompromised hosts, and oral antiviral therapy can be used for mild cases in patients with transient immune suppression 1, 2
- Even without pain, patients should be monitored for potential complications including secondary bacterial infections 1
- Immunocompromised patients may develop chronic ulcerations with persistent viral replication, and secondary bacterial and fungal superinfections can occur 1, 2
Potential Complications
- Lack of rash or late-onset rash in herpes zoster has been associated with delays in diagnosis and increased mortality in some cases 3
- Immunocompromised patients may develop chronic ulcerations with persistent viral replication, and secondary bacterial and fungal superinfections can occur, particularly in immunocompromised hosts 1, 2
Pain Characteristics and Treatment in Shingles
Location and Pain Severity
- Trigeminal or ophthalmic involvement often causes more severe pain, according to the British Journal of Anaesthesia 5
Management of Suspected Shingles
Diagnosis and Treatment
- The American Geriatrics Society recommends considering diagnostic testing if the presentation is atypical, the patient is immunocompromised, or to differentiate from impetigo, with tests including Tzanck preparation, immunofluorescent viral antigen studies, culture, or PCR for definitive confirmation 6
- For a patient like the one described, a medical society may recommend screening for HIV infection, diabetes, malignancy, or immunosuppressive medications as these increase risk and severity, and obtaining laboratory confirmation even with typical presentation 7
Clinical Diagnosis and Management of Herpes Zoster
Diagnostic Considerations
- The American Geriatrics Society recommends confirmatory testing, such as Tzanck preparation, immunofluorescent viral antigen studies, culture, or PCR, for specific situations, including atypical presentations, immunocompromised patients, diagnostic uncertainty, and absence of characteristic pain, as outlined in the Journal of the American Geriatrics Society 8
Treatment and Management
- The Infectious Diseases Society of America suggests that skin biopsy is not indicated for typical herpes zoster and is reserved for immunocompromised patients with atypical skin lesions, as stated in Clinical Infectious Diseases 9, 10, and 11
- The Society of Critical Care Medicine indicates that blood culture has no role in diagnosing localized herpes zoster in an immunocompetent patient with unremarkable systemic examination, according to Critical Care Medicine 12
Clinical Characteristics of Prodromal Pain in Herpes Zoster
Pain Quality
- Patients experience burning, itching, tingling, or paresthesia localized to a single dermatome before any visible skin changes appear, indicating early viral reactivation in the affected nerve segment. 13
Diagnostic Testing for Suspected Herpes Zoster in the Emergency Department
Indications for Laboratory Confirmation
- Laboratory confirmation is recommended for patients who are immunocompromised (e.g., HIV infection, active chemotherapy, organ transplant recipients, chronic immunosuppression) because atypical presentations are more common in this group. 14
Preferred Diagnostic Modalities (when testing is indicated)
- Polymerase chain reaction (PCR) of vesicle fluid is the most sensitive and specific test for varicella‑zoster virus (VZV), approaching 100% sensitivity and specificity, and can detect viral DNA even in crusted lesions. 14
- Direct immunofluorescence (DFA) antigen testing of vesicle fluid provides rapid confirmation of VZV infection and is an accepted alternative when PCR is unavailable. [14][15]
- Tzanck smear of vesicle fluid demonstrates multinucleated giant cells, confirming a herpesvirus infection though it cannot differentiate VZV from HSV; it remains useful as a bedside adjunct. [14][15]
- Viral culture from vesicle fluid can identify VZV but is infrequently used because of longer turnaround time and lower practicality in the ED setting. 14
Tests Not Recommended for Acute Shingles Diagnosis
- Serologic testing (VZV IgG/IgM) does not aid in diagnosing active herpes zoster and should not be ordered. 14
Additional Screening When Herpes Zoster Is Identified
- Diabetes screening should be considered in patients with herpes zoster, as the infection may unmask underlying metabolic disease. 14
- Evaluation for occult malignancy is advised when clinical features raise suspicion, guided by the recommendations of public health authorities. 15
Ophthalmic Involvement Management
- When the rash involves the trigeminal V1 distribution (ophthalmic herpes zoster), an urgent ophthalmology referral is required to assess for ocular complications. 16
Differential Diagnosis of Linear Vesiculopapular Rash
Herpes Simplex Virus (HSV)
- HSV infections typically produce clustered vesicles confined to localized areas (e.g., oral or genital mucosa) and do not follow a dermatomal distribution, which helps distinguish them from herpes zoster. 17
- Recurrence of HSV occurs at the same anatomical site repeatedly, whereas herpes zoster does not show a consistent dermatomal recurrence pattern. 17
- The incubation period for both HSV and varicella‑zoster virus (VZV) ranges from 2 to 10 days after exposure. 17
Larva Currens (Strongyloides infection)
- The rash of larva currens is a rapidly migrating linear urticarial eruption that moves several millimeters per second, a key feature that separates it from the static rash of herpes zoster. 18
- Larva currens most commonly involves the trunk, upper thighs, and buttocks. 18
- This condition is associated with Strongyloides infection and is frequently accompanied by eosinophilia. 18
Management of Atypical Varicella‑Zoster Infection in Immunocompromised Adults
Immediate Diagnostic Approach
- In an immunocompromised adult with fever and limited or absent rash after known varicella exposure, obtain PCR testing from any available vesicular fluid, nasopharyngeal swab, or blood and start empiric IV acyclovir 10 mg/kg every 8 h immediately, without waiting for laboratory confirmation. 19
Clinical Recognition of Atypical Presentations
- Atypical presentations are frequent in immunocompromised patients and may include nonspecific lesions, a limited rash (< 50 lesions) that is predominantly maculopapular rather than vesicular, or complete absence of rash (zoster sine herpete). 20
- Fever can precede rash by 24–72 h or occur without any visible skin findings. 19
- Disseminated varicella may mimic other diseases and can involve visceral organs (hepatitis, pneumonitis) with or without central nervous system manifestations. 19
Diagnostic Testing Strategy
- Do not delay antiviral therapy while awaiting diagnostic confirmation in immunocompromised patients. 19
Antiviral Treatment Protocol
- High‑dose IV acyclovir is the treatment of choice for all VZV infections in immunocompromised hosts. 19
- Recommended dosing: 10 mg/kg IV every 8 h (or 500 mg/m² every 8 h). 19
- Minimum treatment duration: 7–10 days, continuing until all lesions are crusted and no new lesions appear for 48 h. 19
High‑Risk Features Requiring Aggressive Management
- Approximately 30 % of immunocompromised patients develop severe disease with primary VZV infection. 21
- Skin lesions may continue to appear for 7–14 days (versus 4–6 days in immunocompetent hosts). 19
- There is a risk of chronic ulcerations with persistent viral replication and secondary bacterial/fungal superinfection. 19
- Visceral dissemination carries a significant mortality risk if prompt antiviral therapy is not provided. 19
Monitoring During Therapy
- Perform daily assessment for new lesion formation and for visceral symptoms (respiratory distress, hepatitis, neurologic changes). 19
- Consider antiviral resistance if new lesions develop in patients already receiving prophylactic acyclovir or valacyclovir (common in transplant recipients). 19
Infection‑Control Measures (CDC)
- Implement airborne and contact precautions immediately upon suspicion of VZV infection. 22
- Place the patient in a negative‑air‑flow isolation room until all lesions are dry and crusted. 22
- Only healthcare personnel with documented VZV immunity should provide care. 21
- Patients are contagious 1–2 days before rash onset (or before fever onset if no rash) and remain contagious until all lesions are crusted. 20
Exposure Management for Contacts (CDC)
- Identify all susceptible contacts (no prior varicella history, negative serology, or fewer than two vaccine doses). 22
- Administer Varicella‑zoster immune globulin (VariZIG) within 96 h to exposed immunocompromised or pregnant individuals. 22
- Furlough exposed susceptible healthcare workers from days 8–21 after exposure. 22
Common Diagnostic Pitfalls
- Do not wait for a classic dermatomal distribution; disseminated varicella in immunocompromised patients may be bilateral or non‑dermatomal. 19
- Birth before 1980 is not considered reliable evidence of immunity in healthcare or immunocompromised settings due to nosocomial transmission risk. 21
- Breakthrough varicella in previously vaccinated individuals presents with a milder, atypical rash (< 50 lesions, maculopapular) but remains infectious. 20